Neoantigens, which are derived from tumour-specific proteincoding mutations, are exempt from central tolerance, can generate robust immune responses 1,2 and can function as bona fide antigens that facilitate tumour rejection 3 . Here we demonstrate that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma [4] [5] [6] , is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load 1,7 and an immunologically 'cold' tumour microenvironment 8 . We used personalized neoantigentargeting vaccines to immunize patients newly diagnosed with glioblastoma following surgical resection and conventional radiotherapy in a phase I/Ib study. Patients who did not receive dexamethasone-a highly potent corticosteroid that is frequently prescribed to treat cerebral oedema in patients with glioblastomagenerated circulating polyfunctional neoantigen-specific CD4 + and CD8 + T cell responses that were enriched in a memory phenotype and showed an increase in the number of tumour-infiltrating T cells. Using single-cell T cell receptor analysis, we provide evidence that neoantigen-specific T cells from the peripheral blood can migrate into an intracranial glioblastoma tumour. Neoantigen-targeting vaccines thus have the potential to favourably alter the immune milieu of glioblastoma.
, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load 1, 7 and an immunologically 'cold' tumour microenvironment 8 . We used personalized neoantigentargeting vaccines to immunize patients newly diagnosed with glioblastoma following surgical resection and conventional radiotherapy in a phase I/Ib study. Patients who did not receive dexamethasone-a highly potent corticosteroid that is frequently prescribed to treat cerebral oedema in patients with glioblastomagenerated circulating polyfunctional neoantigen-specific CD4 + and CD8 + T cell responses that were enriched in a memory phenotype and showed an increase in the number of tumour-infiltrating T cells. Using single-cell T cell receptor analysis, we provide evidence that neoantigen-specific T cells from the peripheral blood can migrate into an intracranial glioblastoma tumour. Neoantigen-targeting vaccines thus have the potential to favourably alter the immune milieu of glioblastoma.
We designed a phase I/Ib study of personalized neoantigen vaccines for patients with newly diagnosed methylguanine methyltransferase (MGMT)-unmethylated glioblastoma, from whom surgically resected tumour and matched normal cells were analysed to identify neoantigens. Vaccine production occurred during recovery from surgery and administration of radiotherapy. Vaccines 4 contained up to 20 long peptides that were divided into pools of 3-5 peptides (designated as pools A-D) admixed with poly-ICLC (polyinosinic and polycytidylic acid, stabilized with poly-l-lysine and carboxymethylcellulose; see Methods). Following radiotherapy, vaccines were administered in a prime-boost schedule (Fig. 1a) .
Among 10 enrolled patients, we detected a median of 116 somatic single-nucleotide variants per tumour (range, 75-158) with a median of 59 coding mutations per tumour (range, 32-93) using whole-exome sequencing, and the expression of a subset of genes was confirmed by RNA sequencing (RNA-seq) analysis (Supplementary Table 1a Table 2) . No IDH1 or IDH2 mutations were detected. A median of 64.5 HLA binders (range, 30-163) with a half-maximum inhibitory concentration (IC 50 ) < 500 nM was predicted per tumour (Extended Data Fig. 1c and Supplementary Table 3a, b). Two patients were withdrawn because of an insufficient number of actionable neoepitopes or disease progression after radiotherapy. For the remaining 8 patients, the median number and amino acid length of peptides incorporated per vaccine was 12 (range, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and 24 (range, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , respectively (Supplementary Tables 4a, 5) .
Median time from surgery to first vaccination was 19.9 weeks (range, 17.1-24.7 weeks). All eight patients received the five planned priming vaccines but only three completed both booster vaccinations. The other five patients discontinued therapy because of disease progression. Only two patients (7 and 8) did not require dexamethasone during vaccine priming (Fig. 1b) . Treatment side effects were limited to grade 1-2 events. No toxicities were dose-limiting, or resulted in dose delay or treatment discontinuation (Supplementary Table 4b ). All patients died from progressive disease. Median progression-free survival and overall survival were 7.6 months and 16.8 months, respectively (Fig. 1b) .
Circulating immune responses to immunizing peptides (IMPs) were analysed among the five patients who received at least one booster vaccine. Peripheral blood mononuclear cells (PBMCs) were tested for reactivity against pools of overlapping 15-to 16-amino acid peptides (assay peptides (ASPs)) corresponding to the immunizing peptides (Extended Data Fig. 2 ). All three patients (patients 4, 5 and 6) who required dexamethasone during vaccine priming failed to generate interferon-γ (IFNγ) responses (Fig. 2a) . Diffuse early reactivity from patient 6 probably reflects high baseline inflammation that subsequently dissipated. By contrast, patients 7 and 8-who did not receive dexamethasone during vaccine priming-generated robust de novo immune responses against multiple predicted neoantigens as analysed using ex vivo enzyme-linked immunospot (ELISPOT) (Fig. 2a and Extended Data Fig. 3a ). Patient 7 responded primarily to pool C peptides, with CD4 + T cell responses against mutated ARHGAP35 and GPC1 neoepitopes, and preferential reactivity to mutant over wildtype peptides ( 
over wildtype sequences and equivalent reactivity of mutant versus wild-type COX18 was observed (Fig. 2b) . Four of the strongest neoantigenspecific responses from patients 7 and 8 were confirmed to be against processed epitopes ( Fig. 2c and Extended Data Fig. 3d ).
Neoantigen pool-specific CD4 + T cells from patients 7 and 8 were shown to secrete IFNγ, IL-2 and TNF singly and in combination, by direct ex vivo intracellular cytokine staining, thus demonstrating the polyfunctionality of these cells (Extended Data Fig. 3e ). The IFNγ-and IL-2-producing neoantigen-specific T cells were enriched for CD45RO and PD-1 expression, consistent with generation of antigen-experienced memory T cells following vaccination ( Fig. 2d and Extended Data Fig. 3f ). CD8 + T cells from patient 7 that were specific to ARHGAP35 MUT and SLX4 MUT were able to detect minigene-expressed antigens, but did not recognize an autologous tumour cell line when analysed using a TNF ELISPOT (Extended Data Fig. 4a-d) . However, reactivity against tumour-fed dendritic cells was observed for ARHGAP35 MUT CD4
+ T cells and blocked with class II blocking antibodies, indicating that this epitope can be naturally processed and presented (Extended Data  Fig. 4e ).
Five patients (3, 4, 5, 7 and 8) with disease progression at a median of 17.3 weeks (range, 6.7-26.3) following vaccine initiation underwent surgery post-vaccination (Extended Data Fig. 5a ). Multiplex immunofluorescence detected a significant increase in infiltrating CD8
+ T cells at relapse for patients 7 and 8 compared to baseline (average increase 71.0 cells per mm 2 ; 95% confidence interval, 39.1-102.9, P = 0.006; Fig. 3a , Methods and Supplementary Table 6), whereas no increase was observed in patients who received dexamethasone (patients 3, 4 and 5). At relapse, patients 7 and 8 also had increased CD8 + T cells (P = 0.02) and CD4
+ T cells (P = 0.008; few of the intratumoral CD4 + T cells had a regulatory T cell phenotype, Extended Data Fig. 5b ) compared to patients 3, 4 and 5. The extent of immune cell infiltration into the tumour at initial resection was not related to the predicted number of neoantigens (Extended Data Fig. 5c ).
To determine whether the increased infiltration of tumour-associated T cells following vaccination in patients 7 and 8 included neoantigenreactive T cells, we tested whether T cell receptor (TCR) CDR3 α and β sequences-which define clones of T cells with neoantigen-specificitycould be found in tumour tissue in the brain. Our first approach, tested in patient 8, was to leverage clonotype information that was obtained from the analysis of neoantigen-stimulated peripheral blood (Extended Data Fig. 5d ). Using single-cell TCR sequencing (Methods and  Supplementary Table 7) of in vitro neopeptide-stimulated T cells, we  identified 113 and 40 TCRαβ T cell clones from 156 and 63 single cells  following stimulation with SHANK2 MUT and SVEP1 MUT peptides, respectively (Extended Data Fig. 5e and Supplementary Table 8) . We then used this information to track the frequency of the identified individual TCRα and TCRβ chains within bulk TCR-repertoire sequencing data that were generated from matched pre-vaccine and week 16 PBMC samples or the initial and relapsed tumour RNA specimens (Extended Data Fig. 5d 
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and Supplementary Table 9 ). TCRα and TCRβ chains that matched the two dominant SHANK2
MUT and two SVEP1 MUT neoantigen-reactive TCRαβ clones that were isolated from in vitro culture were detected in week 16 but not in pre-treatment peripheral blood, whereas only the SHANK2 MUT TCRα and TCRβ chain sequences were directly detectable in the RNA from the relapse (percentage TCRα unique molecular identifiers (UMI): 0.038 and 0.019; percentage TCRβ UMI: 0.233 and 0.000 for clone 1 and clone 2, respectively) but not the initial tumour (Fig. 3b) . These data suggest that a subset of T cells with specificities that are consistent with neoantigen reactivity and that have been induced by the administration of the vaccine can successfully traffic to the site of disease in this patient.
Because fresh tumour tissue was available at the time of relapse for patient 7, we were able to test a second approach, which was to use T cell clonotype information discovered directly from tumour-associated T cells. We began by freshly isolating single CD3
+ lymphocytes (n = 307) from the post-vaccination tumour of patient 7 and performing single-cell RNA-seq (scRNA-seq), which revealed gene expression information for 81 (26%) CD8
+ and 161 (52%) CD4 + tumourassociated T cells (Extended Data Fig. 6a, b 
SHANK2
COX18 (Fig. 3c) . The co-inhibitory molecules TIM3 (also known as HAVCR2), TIGIT, PD1 (also known as PDCD1), CTLA4 and LAG3 were commonly expressed alone or in combinations of two or three in both CD4
+ and CD8 + cells (Fig. 3d) . A subset of post-vaccination tumour-infiltrating CD8
+ T cells were PD-1 + and their levels increased significantly with vaccination in patients 7 and 8, consistent with prior activation (P = 0.04; Extended Data Fig. 6d ). The low frequency of PD-L1 + SOX2 + tumour cells did not change with vaccination nor with dexamethasone exposure (Extended Data Fig. 6e) .
To determine whether the T cells from patient 7 that recognized the immunizing neoantigens were clonally expanded in the tumour, we used computationally reconstructed TCR sequences from the scRNA-seq data and targeted resequencing of TCR transcripts (Fig. 4a) to identify paired CDR3α and CDR3β sequences. We identified 231 unique TCR clonotypes with 1-8 cells per clonotype from 277 single CD3 + T cells isolated from the relapsed tumour of patient 7 (Extended Data Fig. 7a and Supplementary Table 11a ). Targeted TCR sequencing of post-vaccination circulating neoantigen-reactive T cells from patient 7 was also performed after antigen stimulation to identify any circulating clonotypes that matched those isolated from the relapsed tumour (Extended Data Fig. 7b) Table 12 ) and screened for reactivity against neoantigen peptide pools. The predominant CD8
+ clone (49 cells) was specific to EPT12A, a predicted epitope from the immunizing neoantigen ARHGAP35
MUT of patient 7 (Extended Data Fig. 7d ). Two out of four shared CD4 + TCRs (H02 and F10) were shown to be specific to ARHGAP35 MUT (Fig. 4c) . The H02 and F10 TCRs reacted predominantly to the epitopes ASP34 and ASP35, respectively (Fig. 4c) , and both discriminated between mutant and wild-type peptides (Extended Data In conclusion, neoantigen vaccination is a feasible therapeutic strategy for immunologically cold tumours with a relatively low mutational burden. Although increased CD4 + T cells have been reported in glioblastoma tumours that relapse rapidly 11 , in our small series we show that low levels of infiltrating T cells at diagnosis increased only among patients who generated neoepitope-specific systemic immune responses. Furthermore, we demonstrated that a subset of these T cells within resected intracranial glioblastoma tumours is specific for neoantigens targeted by vaccination. Similar to our melanoma trial 4 , prominent CD4
+ T cell responses against immunizing neoantigens were detected, despite the use of major histocompatibility complex (MHC) class I binding prediction algorithms. While the reasons for this are unknown, similar findings were observed in a recent personal neoantigen vaccine trial using RNA-encoding MHC class I predicted binding epitopes 6 . Optimization of algorithms that predict the immunogenicity of CD8
+ epitopes 12 , and eventually CD4 + epitopes, may help to clarify these results as well as enhance immunogenicity. Two dominant SHANK2 neoantigen-reactive TCRαβ clones (dark and light blue) were identified in T cell lines that were generated from week 16 post-vaccination PBMCs from patient 8 using an IFNγ secretion assay. These clones were detected among post-vaccination (relapse) but not pre-vaccination (initial) tumour-associated TCRαβ sequences using bulk RNA-seq. Two dominant SVEP1-reactive TCRαβ (red and orange) clones were observed in post-vaccination PBMCs but not in brain tumour biopsies. c, Enumeration of the numbers of single CD4
+ and CD8 + tumour-associated T cells that expressed effector cytokines in patient 7, analysed using scRNA-seq. d, CD4 + and CD8 + tumour-associated T cells in patient 7 expressed multiple co-inhibitory receptors based on scRNA-seq.
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Of note, systemic immune responses were limited to patients who did not receive dexamethasone during vaccine priming. This is consistent with observations that dexamethasone indicates poor outcome following checkpoint blockade among patients with recurrent glioblastoma 13 and patients with melanoma with brain metastases 14 , possibly because of systemic depletion of naive and memory CD4 + and/or CD8 + T cells 15 . Despite generating systemic and intratumoral neoantigenspecific immune responses post-vaccination, all patients showed tumour recurrence and ultimately died of progressive disease, indicating that the induced T cell responses must still overcome considerable challenges to produce clinically relevant anti-tumour activity, including tumour-intrinsic defects and immunosuppressive factors in the microenvironment 16, 17 . Low expression of MHC class I in the tumour and the lack of expression of class II (Extended Data Fig. 4b , c) may hinder tumour recognition by neoantigen-specific T cells. However, IFNγ increased MHC I expression in a glioblastoma cell line from patient 7 (Extended Data Fig. 4b ), suggesting that inflammation and T cell-derived IFNγ may increase HLA expression in vivo and aid tumour recognition. Finally, we found that infiltrating T cells post-vaccination-including those with neoantigen specificity-expressed multiple co-inhibitory receptors, consistent with a profound exhaustion phenotype 18 . These observations, combined with anticipated improvements in the timing of vaccine generation, provide a rationale to evaluate neoepitope vaccination combined with immune checkpoint blockade for the treatment of glioblastoma. MUT , a neoantigen targeted by vaccination for patient 7. H02 TCR responds predominantly to ASP34, whereas F10 responds to ASP35. Two-sample two-sided t-tests with Welch correction used for comparison to negative control ovalbumin peptide (OVA). Irr Pool, irrelevant peptide pool; PMA, phorbol 12-myristate 13-acetate; WT, wildtype amino acid. Top left, n = 3 biologically independent samples, all others n = 2 biologically independent samples, each with two technical replicates. Representative data from one of three independent experiments are shown; data are mean ± s.d. d, Distribution of expression levels (log 2 (transcripts per million/10 + 1)) for select genes in CD4 + infiltrating T cells, highlighting the ARHGAP35 MUT -specific T cells, H02 and F10. Blue dots, other cells with TCR clones shared between tumour-associated and neoantigen-reactive T cells in peripheral blood.
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Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Trial design and treatment. The trial protocol and all amendments were approved by the Dana-Farber/Harvard Cancer Center (DF/HCC) Institutional Review Board (IRB). The trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines and was registered at ClinicalTrials.gov (https://clinicaltrials.gov/; NCT02287428). All patients provided written informed consent before study entry, following DF/ HCC IRB protocol approval. All authors attest that the trial was conducted in accordance with the protocol and all amendments; and that they had access to data used for the writing of the manuscript, and vouch for the accuracy and completeness of the data and analyses.
Study eligibility was assessed among patients seen at the Center for NeuroOncology, Dana-Farber Cancer Institute and required: age ≥18 years; Karnofsky performance status ≥70; histopathological confirmation of WHO grade IV glioblastoma (GBM) or variant; tumour MGMT promoter unmethylated by CLIAcertified laboratory; supratentorial tumour with no more than 4 cm in maximal diameter of enhancing tumour on post-operative imaging in any plane; and adequate hepatic, renal and bone marrow function. Patients were excluded if: fewer than five actionable neoepitopes were identified for vaccine generation; they developed disease progression following external beam radiotherapy as defined by Response Assessment in Neuro-Oncology (RANO) 19 ; required more than 4 mg of dexamethasone per day within one week before vaccine initiation; developed active infection; or were pregnant or lactating.
Following surgery, patients received conventional radiation therapy administered at 180-200 cGy per fraction daily for five days per week to a total of approximately 60 Gy. Personalized neoantigen vaccines were prepared using information from fresh tumour and normal tissue obtained at the time of diagnostic resection, as described below. Temozolomide chemotherapy was not administered as this adds only nominal benefit for patients with tumours that lack methylation of the MGMT promoter 20 . The vaccine was administered subcutaneously at least four weeks following completion of external beam radiotherapy. Five priming vaccine doses were initially administered over four weeks (days 1, 4, 8, 15 and 22) followed by two booster doses eight and sixteen weeks later. For each dose, vaccine pools were administered within six hours of thawing in a non-rotating fashion to one of up to four extremities. Concomitant medications deemed necessary for adequate patient care were allowed, including concomitant corticosteroids for symptoms associated with cerebral oedema, but the study vaccine was held for patients requiring more than 4 mg per day of dexamethasone within seven days of vaccine administration. Clinical assessment and monitoring using the RANO criteria 19 and the Immunotherapy Response Assessment in Neuro-Oncology criteria 21 is described in the Supplementary Information. Generation of personalized neoantigen vaccines. The personalized neoantigen vaccines were prepared based on the analysis of whole-exome sequencing (WES) and RNA-seq data generated from fresh-frozen tumours or tumours that were available as formalin-fixed paraffin-embedded (FFPE) tissue, obtained at the time of diagnostic resection. WES of normal tissue was generated from autologous PBMC DNA (Supplementary Table 1a) . Details of the WES and RNA-seq protocols can be found in the Supplementary Information. Patient HLA allotype was assessed using standard class I and class II PCR-based typing (BWH Tissue Typing Laboratory). Coding mutations were identified and personal neoantigens were predicted based on binding affinity analysis to individual HLA alleles using the class I MHC binding prediction tool NetMHCpan version 2.4 22 ; with a cut-off of predicted IC 50 < 500 nM for selected epitopes. WES. CLIA-certified WES was conducted by the Clinical Research Sequencing Platform, Broad Institute (CLIA 22D2055652). Library construction from surgical GBM specimens and matched germline DNA of all 10 patients was performed as previously described 23 . For patients 1, 2 and 9, whole-exome capture was performed using the Agilent SureSelect Human All Exon 44 Mb version 2.0 bait set (Agilent Technologies) 24 . For patients 3, 4, 5, 6, 7, 8 and 10, WES was performed using the Illumina Nextera Rapid Capture Exome version 1.2 bait set. Data were analysed using the Broad Picard Pipeline (version 1.752), which includes de-multiplexing, duplicate marking and data aggregation. . For patients 1, 2 and 9, each sample was transferred into a library preparation that was an automated variant of the Illumina TruSeq Stranded mRNA Sample Preparation Kit. The resulting libraries were quantified with qPCR using the KAPA Library Quantification Kit for Illumina Sequencing Platforms. Data were analysed using the Broad Picard Pipeline, which includes de-multiplexing and data aggregation. RNA-seq data were not available for patient 5, owing to tissue necrosis in the tumour sample. DNA quality control. Broad Institute protocols as previously described 25, 26 were used for DNA quality control. The identities of all tumour and normal DNA samples were confirmed by fingerprint genotyping of 95 common single-nucleotide polymorphisms by Fluidigm Genotyping (Fluidigm). Sample contamination by foreign DNA was assessed using ContEst (version 1.4-437) 27 . Somatic mutation calling. Analyses of WES data of tumour and matched PBMCs (as source of normal germline DNA) from the patients were used to identify the specific coding-sequence mutations, including single-, di-or tri-nucleotide variants that lead to single amino acid missense mutations and small insertions/deletions (indels). Output from Illumina software was processed by the Broad Picard Pipeline to yield BAM files, which contained aligned reads (bwa version 0.5.9, aligned to the NCBI Human Reference Genome Build hg19) with well-calibrated quality scores 25, 28 . Somatic alterations were identified using a set of tools within the 'Firehose' pipeline (https://software.broadinstitute.org/cancer/cga/). Somatic single nucleotide variations (sSNVs) were detected using MuTect (Firehose version 13112); somatic small insertions and deletions were detected using Indelocator (version 1.0) 25 and Strelka (version 1.0.11) 29 . All indels were manually reviewed using the Integrative Genomics Viewer (IGV version 2.4) 30 . All somatic mutations, insertions and deletions were annotated using Oncotator (version 1.4.1) 31 . The ABSOLUTE algorithm (version 1.1) was used to calculate the purity and ploidy of the samples. RNA-seq data were processed using the PRADA software (version 1.1) 32 and tumour transcriptional data were displayed alongside data from normal brain cortical tissue from the GTEx project 33 (analysis V6, dbGaP accession phs000424.v6.p1) and from GBM from TCGA 34 .
Identification of target epitopes for peptide design.
NetMHCpan version 2.4 was used to identify mutation-containing epitopes that are predicted to bind to the MHC class I molecules of each individual patient 22, 35, 36 . Up to 30 peptides of 15-30 amino acids in length (long peptides) that arose from up to 30 independent mutations were selected and prioritized for peptide preparation. Epitopes were chosen for inclusion based on a pre-defined set of criteria in the following rank order: (1) neoantigen open reading frames that included predicted binding epitopes; (2) sSNVs with high predicted affinity (<150 nM) due to changes in anchor residues; (3) sSNVs with high predicted affinity (<150 nM) due to mutations in positions other than anchor residues; (4) NeoORFs with no predicted binding epitopes; and (5) lower affinity (<150-500 nM) versions of (2) and (3).
Mutations in oncogenes were given the highest priority within each ranked group; otherwise epitopes were ranked by predicted mutated peptide affinity. Only sSNVs that demonstrated expression of the mutated allele were used (not available for patient 5). Additionally, a variety of possible biochemical properties (hydrophobicity or presence of multiple cysteines), which may affect the synthesizability or solubility of the long peptide were considered. Synthesis of long peptides, pooling and final vaccine preparation. Good Manufacturing Practice (GMP) peptides 20-30 amino acids in length were synthesized by standard solid-phase synthetic peptide chemistry and purified using reverse phase high performance liquid chromatography (CSBio). Each vaccine consisted of up to 20 distinct peptides that were grouped into four pools (A, B, C and D), each consisting of up to five peptides, with the intent of separating peptides that bind to the same MHC allele into different pools to decrease potential antigen competition at the draining lymph node. For each dose, the vaccine pools were administered within six hours of thawing, in a non-rotating fashion to one of up to four extremities. The final concentration of peptides per pool was 400 μg ml
, with a goal of administering a final dose of 300 μg of each peptide per vaccine injection. Each vaccine pool was filter-sterilized and frozen at −80 °C. Following final testing for identity, sterility and endotoxins, vaccine pools were released for clinical use. On the day of vaccine administration, each pool was thawed and 0.75 ml was mixed with 0.25 ml (0.5 mg) of polyinosinic and polycytidylic acid, stabilized with poly-l-lysine and carboxymethylcellulose (poly-ICLC, Hiltonol, Oncovir) for a final administration volume of 1.0 ml per pool. Patient samples and cell lines. Tumour samples and heparinized blood were obtained from study subjects on IRB-approved protocols at the DFCI. Patient samples were de-identified and assigned a study-specific tracking number. PBMCs were collected via leukapheresis before initiation of external beam radiotherapy (pre-treatment baseline) and approximately eight weeks following completion of priming vaccine dosing. PBMCs were isolated by Ficoll/Hypaque density-gradient centrifugation (GE Healthcare) and cryopreserved with 10% dimethyl sulfoxide in FBS (Sigma-Aldrich). Cells and serum from patients were stored in vapourphase liquid nitrogen until the time of analysis. The GBM cell line of patient 7 was established from tumour cells collected from surgical resection at initial diagnosis (Extended Data Fig. 4a) ; the protocol for generation is described in the Supplementary Information. Jurkat∆αβ is a TCR-deficient Jurkat cell line (genetically engineered to lack endogenous TCR expression by CRISPR-Cas9 targeting, with stable expression of CD28, CD8 and CD4) obtained from A. Muraguchi and H. Kishi (Department of Immunology, University of Toyama). This cell line has been confirmed to be mycoplasma-free and has been wellcharacterized in previous publications 10, 37 . Antigen formats for immune monitoring. Assay (ASPs) and predicted class I epitope peptides (EPTs) were synthesized and lyophilized (from either JPT Peptide Technologies or RS Synthesis; >80% purity) in a manner previously described 4 . ASPs were 15-16 amino acids long and overlapped by at least 11 amino acids, covering the immunizing peptide sequence. EPTs were 9-10 amino acids predicted to be MHC class I restricted neoepitopes. Minigenes were constructed for the ASP and EPT peptides that elicited a response from patient PBMCs. Autologous CD19 + B cells were isolated from pre-vaccine PBMCs and were nucleofected with minigenes using program X-001 (Amaxa Cell Line Nucleofector Kit V; Lonza). The complete protocol is described in the Supplementary Information. For experiments testing direct tumour recognition, GBM cell lines from patient 7 were dissociated and passaged using Accutase (Sigma-Aldrich) and dissociated using Versene (Gibco, ThermoFisher). The protocol for cross-presentation assays 38 is described in the Supplementary Information. Generation and detection of patient neoantigen-specific T cells. ELISPOT assays. Screening ex vivo IFNγ ELISPOT assays on PBMCs stimulated for 18 h with synthesized screening peptides consisting of ASP and EPT peptides were performed. The averages of responses to DMSO, HIV-GAG or OVA peptide for each time point were subtracted from experimental wells for background correction 39 . If no responses were observed, additional in vitro stimulation with the peptide pool was performed for up to 21 days. Upon detection of a positive ELISPOT response (defined as at least 55 spot-forming cells (SFC) per 10 6 PBMCs or a ≥3-fold increase over baseline), the peptide pools were allocated into sub-pools to deconvolute the peptide pool to determine the immunogenic peptide(s) per pool. PBMCs were cultured in DMEM GlutaMAX medium supplemented with HEPES, β-mercaptoethanol, sodium pyruvate, nonessential amino acids, penicillin-streptomycin (Gibco, ThermoFisher) and 10% AB-positive heat-inactivated human serum (Gemini Bioproduct). For in vitro expansion (pre-stimulation) of antigen-specific T cells, PBMCs were stimulated in 24-well cell-culture plates at 5 × 10 6 cells per well with individual (10 μg ml −1 ) or pooled peptides (each at 10 μg ml ; Amgen) was added. Half-medium change and supplementation of cytokines were performed as necessary, as previously described 40 . After 10-21 days, T cell (referred to as 'T cell lines') specificity was tested against peptide, minigenes or the autologous tumour by IFNγ or TNF ELISPOT in DMEM medium supplemented with penicillin-streptomycin and 10% FBS (complete DMEM) as previously described 4 . For deconvolution of CD4 + and CD8 + T cell responses, CD4
+ and CD8 + T cells were enriched immunomagnetically (CD8 + , CD4 + T cell Isolation Kit beads, Miltenyi Biotec) before plating for ELISPOT. Intracellular cytokine staining. PBMCs were thawed and rested overnight in DMEM GlutaMAX medium (Gibco, ThermoFisher) supplemented with 10% AB-positive heat-inactivated human serum (Gemini Bioproduct), nonessential amino acids, HEPES, β-mercaptoethanol, sodium pyruvate, penicillin-streptomycin (Gibco, ThermoFisher) and 20 ng ml −1 IL-7 (Peprotech). On the next day, PBMCs were stimulated with 10 μg ml −1 vaccine peptide pools, HIV-GAG peptide (negative control) or 1% phytohaemagglutinin (PHA) (positive control) overnight. Stimulated PBMCs were treated with GolgiStop (BD Biosciences), according to the manufacturer's recommendations, for 8 h the following day. After treatment, PBMCs were stained for 30 min at room temperature with a fixable dead cell stain (Thermofisher), anti-CD3 (BV605), anti-CD8 (PerCP-Cy5.5), anti-CD4 (BV650) (BD Biosciences), anti-CD45RO (APC-Cy7) and anti-PD-1 (PE) (Biolegend). Cells were fixed and permeabilized (Fixation/Permeabilization Solution Kit, BD Biosciences). Intracellular cytokines were stained with anti IFNγ (PE-Cy7), IL-2 (APC) and TNF (AF700) (BD Biosciences) for 1 h at 4 °C. Cells were washed with permeabilization buffer and fixed (1% paraformaldehyde solution, Sigma-Aldrich). Cells were analysed using a BD Fortessa flow cytometer. Live lymphocytes were gated on forward and side scatter and live/dead staining, and CD3 positivity was used to determine the T cell gate. CD4
+ versus CD8 + cells were gated and cytokine staining was plotted on each population using the program FlowJo. Multiplex immunofluorescence. Staining was performed using BOND RX fully automated stainers (Leica Biosystems). The target antigens, antibody clones and dilutions for markers, as well as the details of controls, are listed in Supplementary  Table 6 . Image acquisition was performed using the Mantra multispectral imaging platform (Vectra 3, PerkinElmer). Areas with non-tumour or residual normal tissue (that is, residual lymph node) were excluded from the analysis. Representative regions of interest were chosen by the pathologist, and multiple fields of view were acquired at 20× resolution as multispectral images. Cell identification was performed as described 41 , using supervised machine learning algorithms within Inform 2.3 (PerkinElmer). Thresholds for 'positive' staining and the accuracy of phenotypic algorithms were optimized and confirmed by the pathologist (S.J.R.) for each case. The protocol is described in full in the Supplementary Information. Processing of GBM and PBMC specimens for scRNA-seq. Surgically resected GBM tissue from patient 7 was obtained on ice within 30 min of lesion excision. The tumour specimen was mechanically disrupted into small pieces with a disposable, sterile scalpel and further dissociated into a single-cell suspension using the enzymatic brain dissociation kit (P) from Miltenyi Biotec, following the manufacturer's protocol. Fc receptor blocking was performed on the total cell suspension using Human TruStain FcX (Biolegend). The cell suspension was subsequently stained for flow cytometry using antibodies against BV605-conjugated CD45 (HI30), BV510-conjugated CD3 (HIT3a) from BD Bioscience, PE-Cy7-conjugated CD4 (OKT4), PerCP-Cy5. ). The medium was replenished as necessary over three weeks of culture, after which CD8 + T cells were enriched (CD8 magnetic beads, Miltenyi Biotec), rested overnight in cytokine-free medium and then stimulated overnight with autologous APCs (CD4-and CD8-depleted PBMCs) loaded with peptide (10 μg). Subsequently, IFNγ-producing neoantigen-responsive cells were stained and sorted as single cells into 96-well plates, as above. scRNA-seq data generation and analysis. scRNA-seq data were generated using a modified version of the Smart-seq2 protocol, as previously described 42 . As we previously reported 43 , we mapped the scRNA-seq reads to the human transcriptome (hg19) using Bowtie (v1.2.0) 44 and quantified gene expression as transcripts per million (TPM) using RSEM (v1.1.17) 45 . We further normalized the data as E = log 2 (TPM / 10 + 1) and evaluated the number of genes detected in each cell and the average expression (E) of T cell markers (CD2, CD3D, CD3E and CD3G); 307 out of 384 cells that were sequenced had at least 1,800 detected genes and genes with average E marker genes > 2 were retained for further analysis. Genes were retained for further analysis if their average TPM across all cells that were retained for analysis was above 3. Next, we defined expression scores, for each cell, for the following genes and signatures, based on the average E of the gene(s) indicated in parenthesis: (1) CD4 (CD4); (2) CD8 (CD8A and CD8B); (3) regulatory T (T reg ) cells (FOXP3 and IL2RA) ; (4) cytotoxic T cells (PRF1, GZMA, GZMK, NKG7 and CST7); (5) naive/memory T cells (CCR7, TCF7, SELL, CD27, CD28 and IL7R); and (6) co-inhibitory receptors (PD1, CTLA4, TIGIT, LAG3 and TIM3). Note: GZMB was excluded owing to minimal expression across all cells. We classified cells into corresponding classes if they passed the average expression threshold (>3) for the gene/signature of the class, but were lower than another threshold (<1) for the alternative class. Thus, cells were classified as CD4 + and CD8 + by the corresponding score being larger than three and the alternate score being smaller than one, with remaining cells being considered unresolved (ND, not determined) and excluded from further analysis. CD4
+ cells were further classified as T reg cells or as cytotoxic T cells if they had T reg or cytotoxic scores higher than three; no cells had scores higher than three for both signatures.
We attempted to computationally reconstruct TCRs from each single-cell transcriptome, including those that did not pass our quality control for gene expression, using TraCeR (version 0.4.0) 46 . We next defined putative clones by grouping cells having identical reconstruction of the TCRα or TCRβ chains. This was performed for the tumour-associated T cells as well as for the T cells from peripheral blood samples, to distinguish clonotypes that were specific to the tumour from those that are shared with the blood. Targeted TCR sequencing. Targeted amplification of TCR transcripts was performed in a 96-well plate format using single-cell-amplified cDNA libraries (before fragmentation), either from the Smart-seq2 procedure described above or prepared using the NEBNext Single Cell/Low Input cDNA Synthesis & Amplification Module (New England BioLabs E6421L). The protocol uses RNase H-dependent Letter reSeArCH polymerase chain reaction (rhPCR) technology to improve the specificity for differential amplification of TCR alleles 47 and uses double indexing to avoid the problem of index switching 48 . The sequences of all primers (Integrated DNA Technologies) used in the protocol are provided in Supplementary Table 7 . Sequencing was performed on the Illumina MiSeq with the 300-cycle Reagent Kit version 2 (MS-102-2002). The protocol is described in full in the Supplementary Information.
The raw single-cell TCR sequencing data were demultiplexed using the well-specific dual indices. For each well, the paired-end reads were first aligned to V primers and C primers to separate the TRA and TRB reads (e < 0.001, BLAST version 2.2.30+) 49 . Only the reads with consistent V and C primers aligned were kept (for example, one read with R1 aligned to a TRAV primer and R2 aligned to the TRAC primer). The separated TRA and TRB reads were aligned to TCR reference sequences using MiXCR-2.1.5 50 , and a set of clonotypes was assembled for each gene in each well. The most abundant productive α and β clonotypes were selected and paired for each well.
The protocol was adapted for the analysis of bulk RNA by substituting a reverse transcriptase reaction for the single-cell cDNA library, as described in the Supplementary Information. RNA extraction for bulk TCR sequencing. Banked frozen GBM tumour biopsies of patient 8 at diagnosis and at relapse were physically dissociated using a tissue homogenizer in QIAGEN-RNeasy Mini kit buffers and RNA was extracted as described in the manufacturer's protocol. Cryopreserved PBMCs collected from patient 8 pre-and post-vaccine were thawed and rested overnight in DMEM GlutaMAX medium (Gibco, ThermoFisher), supplemented with 10% AB-positive heat-inactivated human serum (Gemini Bioproduct), nonessential amino acids, HEPES, β-mercaptoethanol, sodium pyruvate, penicillin-streptomycin (Gibco, ThermoFisher) and 20 ng ml −1 IL-7 (Peprotech). On the next day, 5 × 10 6
PBMCs were collected and total RNA was extracted using a QIAGEN RNeasy Mini kit. Generation and antigen-specificity testing of TCR-expressing Jurkat reporter cell lines. The TCR cloning and expression protocol 10 is described in the Supplementary Information. We used TCR-deficient Jurkat cells (Jurkat∆αβ) 37 transduced to express CD4 and CD8 as reporter cells. To assess antigen specificity of the cloned TCRs, we pulsed dendritic cells derived from patient PBMCs with candidate peptides (10 μg ml −1 unless specified otherwise) for 2 h in complete RPMI. Reporter cells stably expressing TCR were co-cultured in 96-well round-bottom plate with pulsed dendritic cells, in a ratio of 20:1 (0.5 × 10 6 Jurkatexpressing TCR cells to 2.5 × 10 4 dendritic cells) in complete RPMI. After 24 h at 37 °C and 5% CO 2 , the supernatant was collected and diluted 1:2 with ELISA Assay Diluent (Biolegend) and IL-2 production was measured using the Human IL-2 ELISA MAX Standard Kit (Biolegend) according to the manufacturer's instructions. OVA peptide was used as a negative control and PMA/ionomycin was used as a positive control. Statistical considerations. This study incorporated co-primary end points of safety and feasibility. Safety was assessed using a standard dose escalation design. With a true probability of dose-limiting toxicity (DLT) estimated to be ≤10%, 0 or 1 DLT in a cohort of five patients was associated with a 92% probability of proceeding to the dose expansion phase. Patients were deemed evaluable for DLT if they received at least three study vaccinations or experienced DLT. A stopping rule for unexpected toxicity during the expansion phase was incorporated that required interruption of further accrual to the dose expansion if four or more patients experienced DLT. Feasibility was assessed as the percentage of patients who were able to have at least 10 actionable neoepitope vaccine peptides generated and the percentage of patients who were able to initiate study vaccination within 12 weeks of diagnostic surgery. Feasibility was defined as at least 50% of the patients (1) having at least 10 actionable peptides for vaccine production and (2) initiating vaccine therapy within 12 weeks of diagnostic surgery.
Changes between pre-treatment and post-vaccination PBMC immune responses were assessed using the Wilcoxon signed-rank test. All P values were two-tailed and reported without adjustment for multiple comparisons (Fig. 2a) . Summary statistics were used to assess other measures of immune cell status. For the ELISPOT analyses, data for each pool were normalized against the control by taking the average of the control for each time period and subtracting it from each of the three replicate pool measurements at that time. If the normalized value was less than zero, then zero was substituted. The normalized numbers of SFC per assay per unit time were estimated using repeated-measures regression with an unstructured covariance to model the variation over time. In the model, assay, time and the interaction of assay and time were predictors. Estimates of the average numbers of SFC for each assay were based on least-squares means. To control for multiplicity within a time point, P values for the comparisons of each pool against zero were adjusted using the Benjamini-Hochberg procedure, thereby maintaining an overall type-I error of 0.05 at each time.
Investigations of changes in the T cell infiltrate between initial and relapse tumour resection specimens from patients 3, 4, 5, 7 and 8 were based on repeated-measures linear models with the number of cells per mm 2 as the dependent variable and treatment, time and their interaction as independent variables (Fig. 3a and Extended Data Fig. 6d, e) . Comparisons between dexamethasone/no dexamethasone arms were made, and because of the multiple measurements per patient at each time point, the covariance structures of all models were adjusted to allow for clustering by patient within the data. P values were based on model F-tests. Statistical significance was defined as P < 0.05. There were no corrections for multiple comparisons.
Rates of detection of ASP35 and ASP34 specificity among single T cells in the brain at relapse and in the PBMCs collected at week 16 (patient 7) were compared using a Poisson test, with statistical significance defined as P < 0.05.
The distributions of progression-free and overall survival are summarized using the method of Kaplan-Meier. Median percentages are presented with standard errors estimated using log(−log(outcome)) methodology. Follow-up duration, which was defined as the time from diagnosis to death or database cut-off, was calculated for all patients. 
Data availability
WES and bulk RNA-seq data generated and analysed during the current study are available through dbGaP (https://www.ncbi.nlm.nih.gov/gap) with accession number phs001519.v1.p1. All other data are available from the corresponding author upon reasonable request.
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Extended Data Fig. 3 | Neoantigen-specific T cell responses generated by vaccine in patients. a, Ex vivo IFNγ ELISPOT observed in a patient treated with dexamethasone during vaccine priming (patient 4, left) showed no response at 12 weeks after vaccination, whereas a patient who did not receive dexamethasone (patient 8, right) showed strong response already at 8 weeks after vaccination. DMSO, dimethyl sulfoxide; CEF, peptides from cytomegalovirus, Epstein-Barr virus and influenza virus. b, Deconvolution of post-vaccination CD4
+ and CD8 + immune responses following stimulation to the neoantigen assay peptide pools using IFNγ ELISPOT assays. n = 3 biologically independent samples, data are mean ± s.d. c, SLX4 MUT MUT and SLX4 MUT ) show enrichment of particular clonotypes. b, Sorting strategy for isolating neoantigen pool-reactive CD4 + T cells from peripheral blood ex vivo. Negative control, DMSO. c, Six TCRs identified in both tumour-associated and neoantigen-reactive T cells from peripheral blood were successfully cloned and expressed in the reporter cell line, as verified by stabilized CD3 surface expression; this experiment was repeated twice in independent experiments. The CDR3 sequences of these TCRs can be found in Supplementary Table 9 . d, The largest CD8 + clone detected among the neoantigen-reactive T cell lines established from peripheral blood of patient 7 was experimentally confirmed to be specific for EPT12A, the MHC class I predicted epitope of ARHGAP35
MUT . Two-sample twosided t-tests with Welch correction were used for the comparisons; n = 4 biologically independent replicates; data are mean ± s.d. e, CD4
+ ARHGAP35-specific H02 and F10 TCRs (as described in Fig. 4 ) discriminate between the mutant and wild-type form of the peptide. n = 2 biologically independent samples, each with two technical replicates; data are mean ± s.e.m. f, The ARHGAP35 mutation in the tumour of patient 7 is present in both the initial and relapse tumour specimens, as visualized by the IGV 30 .
1 nature research | reporting summary 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested 
Software and code
Policy information about availability of computer code For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability WES, scRNA-seq, bulk RNA-seq, and TCR sequencing data generated and analyzed during the current study are available through dbGaP (phs001519.v1.p1). All other data are available from the corresponding author upon reasonable request.
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Sample size
This was a phase I study to assess safety and feasibility of the vaccination strategy. It was conducted in cohorts with n=5, with a goal of treating 10 patients as specified in the study protocol. No dose escalation was planned; however, if dose-limiting toxicities were observed in the first 5 patients, the next 5 would be treated with a 50% dose reduction of poly-ICLC. Sample size justification is described in Statistical Considerations section of Supplemental Methods.
Data exclusions No data exclusions
Replication
Laboratory studies were performed in multiple wells for each condition examined, and means with SD or SEM, along with the numbers of replicates, are reported.
Randomization There was no randomization in this phase Ib clinical trial.
Blinding
As there was no randomization, there was no blinding in this phase Ib clinical trial. Patient samples were de-identified and assigned a study specific tracking number.
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